BridgeBio Pharma BBIO Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$732.94M-34.9% | -$543.35M+16.8% | -$653.25M-34.8% | -$484.65M+17.4% | ||
| $5.43M-10.6% | $6.08M-6.5% | $6.49M-4.1% | $6.77M+15.9% | ||
| $133.02M+38.9% | $95.8M-11.9% | $108.71M+18.7% | $91.56M-8.0% | ||
| —— | —— | $8.91M— | —— | ||
| —— | $2.97M+119% | -$15.33M-1.0% | -$15.17M— | ||
| $25.31M— | $0— | $0— | —— | ||
| —— | —— | $2.78M— | —— | ||
| $23.02M+35.5% | $16.99M— | —— | —— | ||
| —— | —— | $2.7M+135% | -$7.67M-280% | ||
| $77.81M+1,757% | $4.19M+19.1% | $3.52M— | —— | ||
| —— | —— | $803K+134% | -$2.36M+67.8% | ||
| -$11.43M— | —— | -$5.44M— | —— | ||
| $0— | —— | $18.31M— | —— | ||
| —— | —— | $4.03M— | —— | ||
| -$21.16M+20.4% | -$26.59M— | $0— | $0+100% | ||
| -$6.55M-10.9% | -$5.9M-22.2% | -$4.83M+22.7% | -$6.25M-2.0% | ||
| -$445.91M— | —— | -$527.72M-25.8% | -$419.49M+15.8% | ||
| $1.1M+17.6% | $933K-28.6% | $1.31M-72.9% | $4.82M-63.6% | ||
| —— | $93.81M+216% | $29.73M— | —— | ||
| $2.3M— | —— | $0— | $0— | ||
| $8.5M+6.5% | $7.98M— | $0-100% | $1.5M-95.7% | ||
| —— | $64.02M+18.3% | $54.1M-88.1% | $453.15M— | ||
| —— | $0— | $0— | $0-100% | ||
| —— | —— | $0— | $0— | ||
| —— | —— | $0-100% | $20.49M— | ||
| $0— | —— | $450.26M+9,180% | $4.85M— | ||
| —— | —— | -$801K— | $0— | ||
| $14.23M+89.0% | $7.53M+9.4% | $6.88M+341% | $1.56M-67.1% | ||
| —— | —— | $0— | —— | ||
| —— | $754.19M— | —— | —— | ||
| -$111.1M— | —— | -$22.15M— | —— | ||
| —— | $91.34M+49.5% | $61.11M+12.2% | $54.44M+82.9% | ||
| —— | —— | $8.91M— | —— | ||
| $0-100% | $178.32M+14,469% | -$1.24M— | —— | ||
| —— | —— | $0— | —— | ||
| -$72.61M-133% | -$31.18M— | $0— | $0— | ||
| $7.16M— | —— | —— | -$4.31M— | ||
| -$11.43M— | —— | -$5.44M— | —— | ||
| $23.02M+35.5% | $16.99M— | —— | —— | ||
| -$6.55M-10.9% | -$5.9M-22.2% | -$4.83M+22.7% | -$6.25M-2.0% | ||
| -$1.11M+27.8% | -$1.54M-200% | $1.55M+114% | -$10.97M-207% | ||
| —— | —— | $2.7M+135% | -$7.67M-280% | ||
| $125.14M— | —— | $0— | —— | ||
| —— | —— | $4.03M— | —— | ||
| —— | —— | $803K+134% | -$2.36M+67.8% | ||
| $0— | $0-100% | $10.21M— | —— | ||
| $8.5M+6.5% | $7.98M— | $0-100% | $1.5M-95.7% | ||
| —— | $95M+15.1% | $82.55M— | —— | ||
| —— | —— | $0— | —— | ||
| —— | —— | -$801K— | —— | ||
| —— | —— | $3.4M— | —— | ||
| $43K-84.6% | $279K— | —— | —— | ||
| —— | —— | —— | $0-100% | ||
| -$5.59M+3.9% | -$5.82M+44.8% | -$10.53M-200% | -$3.51M-65.3% | ||
| —— | —— | —— | —— | ||
| -$447.01M— | —— | -$529.03M-24.7% | -$424.32M+17.0% | ||
| -$447.01M— | —— | -$529.03M-24.7% | -$424.32M+17.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BridgeBio Pharma generate?
- BridgeBio Pharma (BBIO) generated -$444.0M in operating cash flow over the trailing twelve months.
- What is BridgeBio Pharma's free cash flow?
- After $1.2M of capital expenditures, BridgeBio Pharma's free cash flow was -$445.1M over the trailing twelve months, up 44.0% year over year.
- Where does BridgeBio Pharma's cash flow data come from?
- Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
